![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate to Present at Cantor Fitzgerald's Inaugural Healthcare Conference
July 01, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, July 1, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology, today announced plans to present a company overview at Cantor...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Appoints Former CDC Division Chief Thomas Monath to Board of Directors
June 17, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a breakthrough vaccine technology platform, today announced the appointment of Thomas P. Monath,...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Advances Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, into Phase 2 Study
June 03, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, June 3, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
Vaxin Names Elizabeth Adkins Czerepak as Chief Financial Officer
April 13, 2015 08:30 ET
|
Vaxin Inc.
GAITHERSBURG, MD--(Marketwired - Apr 13, 2015) - Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate to Present at Needham & Company 14th Annual Healthcare Conference
April 07, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, April 7, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced plans to present
at the Needham & Company 14th...
Vaxin CEO to Present at Future Leaders in the Biotech Industry Conference
March 17, 2015 08:30 ET
|
Vaxin Inc.
GAITHERSBURG, MD--(Marketwired - Mar 17, 2015) - Vaxin, a clinical stage vaccine development company, today announced that CEO Bill Enright will present at the Future Leaders in the Biotech...
Vaxin Enters Definitive Agreement to Acquire Immune Targeting Systems (ITS); Secures $16M in New Financing
February 17, 2015 08:30 ET
|
Vaxin Inc.
GAITHERSBURG, MD--(Marketwired - Feb 17, 2015) - Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Receives Extension of Contract from BARDA for Development of Seasonal and Pandemic Influenza Vaccines
February 17, 2015 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Feb. 17, 2015 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology, today announced that it has
executed a contract modification...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Initiates Phase 1b/2 Clinical Trial of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, in Elderly
December 08, 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Dec. 8, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering a
breakthrough vaccine technology platform, today announced the
initiation of a double-blind,...
![VaxInnate Logo](/news-release/logo/313305/0/313305.jpg?lastModified=12%2F09%2F2016%2023%3A16%3A03&size=2)
VaxInnate Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints
November 11, 2014 08:00 ET
|
VaxInnate Corporation
Cranbury, NJ, Nov. 11, 2014 (GLOBE NEWSWIRE) -- VaxInnate Corporation, a biotechnology firm pioneering
next-generation vaccine technology, announced today that enrollment
has concluded in the Phase 1...